Russia’s Geropharm and Belarusian state-owned firm Belmedpreparaty have signed a licensing agreement to localize the production of insulin analogs glulisine and glargine in 100 and 300 unit doses. The deal was inked on September 29 at the Innoprom. Belarus international industrial exhibition in Minsk, according to the Belarus Today news outlet. The technology transfer is expected to be completed by the end of 2026.
The partners had earlier completed the localization of another insulin, aspart, this year. It is expected that the collaboration will expand the range of manufactured drugs.
Alexander Zhadan, General Director of Belmedpreparaty, said the partnership with Geropharm would promote the provision of insulin to diabetes patients in Belarus. He noted that cooperation with a leading full-cycle Russian insulin manufacturer helps develop the company’s competencies in producing high-tech drugs and fosters industrial cooperation within the Union State and the EAEU.
The Innoprom. Belarus exhibition runs from September 29 to October 1 at the Minsk International Exhibition Center. The event is organized by Russia’s Ministry of Industry and Trade and Belarus’ Ministry of Industry. The exhibition features more than 510 companies, including around 290 from Russia, and is expected to be a key platform for showcasing new technologies and discussing interregional cooperation. Attendance is projected to be around 10,000 people.
